Long-Term Considerations for PBC Treatment Options

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how sustained treatment success in primary biliary cholangitis (PBC) requires regular monitoring of biochemical response markers, assessing patient adherence, managing potential adverse effects, and making timely adjustments to treatment strategies based on individual patient responses to seladelpar and elafibranor.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

Now Viewing

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

EP: 11.Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

EP: 12.Long-Term Safety of Second-Line Therapies for PBC

EP: 13.Best Practices in Switching PBC Therapies

EP: 14.Monitoring Patients Transitioning From Obeticholic Acid

EP: 15.Additional Considerations With PBC Therapies

Video content above is prompted by the following:

As new data emerge regarding the durability of response with seladelpar and elafibranor, what are the key long-term considerations for maintaining treatment efficacy in PBC?

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!